Hans Vemer, MD, president of Organon, said, "We are thrilled to receive our second major FDA drug approval in less than three weeks. The introduction of RAPLON will allow Organon to continue its leadership position in the field of neuromuscular blocking agents," said Dr. Vemer. "We continue to be an innovator in this field, and a reliable supplier offering a full range of products for anesthesiologists."
"RAPLON offers an excellent alternative to both succinylcholine and mivacurium for patients undergoing outpatient (ambulatory) surgery because of its rapid onset and short recovery and favorable side effect profile," said Paul F. White, PhD, MD, professor and holder of the Margaret Milam McDermott Distinguished Chair of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas.
Source
Why, you ask?
Ed has the scoop!
No comments:
Post a Comment